Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with ...

NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 TherapyNUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated ...

Designation supported by results from multiple dose cohorts from the Phase 1/1b trial of ficerafusp alfa in 1L HPV-negative R/M HNSCCBOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc.

FDA fast track designation for NG-350A aims to expedite its development for mismatch repair-proficient locally advanced ...

EFFICIENT DIAGNOSES Siteman is exploring new avenues of treating cancer with theranostics, which combines diagnostic testing and therapy. Available through the center at Barnes-Jewish Hospital and ...

With the 2025 European Society of Medical Oncology (ESMO) Congress kicking off on Friday, October 17, in Berlin, Germany, Targeted Oncology is bringing you background on the most exciting abstracts ...

The HARMONi-6 trial result has been selected as a Late-Breaking Abstract (LBA) for the 2025 ESMO Congress. Professor Lu Shun, Director of the Oncology Department at Shanghai Chest Hospital, presented ...

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that its latest research has been accepted for poster presentation at the ...

Bicycle Therapeutics' strong cash position and planned workforce reduction extend the operational runway into 2028. See why ...

Welcome to The Pharma Letter’s real-time coverage of the 2025 European Society of Medical Oncology (ESMO) Congress, taking ...

NG-350A has received FDA fast track designation for mismatch repair-proficient locally advanced rectal cancer, addressing a ...